FDA Approves Iberdomide Combination for Multiple Myeloma, First Based on MRD-Negative Data

The FDA has approved Bristol-Myers Squibb's iberdomide in combination with daratumumab and dexamethasone for adults with relapsed or refractory multiple myeloma. This marks the first approval in this setting to rely on minimal residual disease (MRD)-negative complete response data, indicating a deep and sustained treatment response. This development offers a new therapeutic option for patients who have undergone at least one prior line of therapy.